Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurinia Pharmaceuticals Inc.

www.auriniapharma.com

Latest From Aurinia Pharmaceuticals Inc.

Keeping Track: J&J Submits Ponesimod NDA For MS; US FDA Clears Epclusa For Pediatric HCV

The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.

US FDA Performance Tracker Drug Review

GSK Plans Benlysta Expansion In Lupus Nephritis Based On Successful Phase III

Benlysta was an early pioneer in systemic lupus erythematosus, but GSK now plans to expand the drug into the acute area, active lupus nephritis, with a filing in 2020.

Immune Disorders Clinical Trials

Finance Watch: IPOs Are In A Slump, But Already Public Companies Have Rallied

Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m. 

Financing Business Strategies

Aurinia Closing In On Lupus Nephritis With Voclosporin

Canada’s Aurinia Pharmaceuticals expects to file a US NDA in the first half of next year on the use of its next-generation calcineurin inhibitor, voclosporin, in lupus nephritis, a condition with no approved therapies.

Renal Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Ophthalmic
  • Alias(es)
  • Isotechnika Pharma Inc.
  • Isotechnika Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Aurinia Pharmaceuticals Inc.
  • Senior Management
  • Peter Greanleaf, CEO
    Dennis Bourgeault, CFO
    Neil Solomons, MD, CMO
    Michael Martin, COO
  • Contact Info
  • Aurinia Pharmaceuticals Inc.
    Phone: (250) 708-4272
    1203-4464 Markham St.
    Victoria, V8Z 7X8
    Canada
UsernamePublicRestriction

Register